Corcept Therapeutics Files 8-K on Operations & Financial Condition

TL;DR

**Corcept Therapeutics just dropped an 8-K, giving a peek into their latest financial results and other key updates.**

AI Summary

Corcept Therapeutics Incorporated filed an 8-K on January 8, 2024, to report on its results of operations and financial condition, as well as other events. This filing indicates that the company is providing an update on its financial performance and other significant developments. For investors, this matters because it offers a timely glimpse into the company's health and any recent material changes that could affect its stock price, allowing them to make informed decisions.

Why It Matters

This filing provides a current snapshot of Corcept Therapeutics' financial health and recent events, which is crucial for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial condition and other events, not indicating any immediate new risks.

Analyst Insight

A smart investor would review the full 8-K filing to understand the specific details of the 'Results of Operations and Financial Condition' and 'Other Events' to assess any material impacts on Corcept Therapeutics' valuation or future outlook.

Key Players & Entities

• Corcept Therapeutics Incorporated (company) — the registrant filing the 8-K
• January 8, 2024 (date) — date of earliest event reported and filing date
• Delaware (company) — state of incorporation for Corcept Therapeutics
• 000-50679 (company) — Commission File Number for Corcept Therapeutics
• 77-0487658 (company) — I.R.S. Employer Identification No. for Corcept Therapeutics
• 149 Commonwealth Drive, Menlo Park, CA 94025 (company) — principal executive offices address for Corcept Therapeutics
• (650) 327-3270 (company) — telephone number for Corcept Therapeutics
• CORT (company) — trading symbol for Corcept Therapeutics Common Stock
• The Nasdaq Stock Market (company) — exchange where Corcept Therapeutics Common Stock is registered

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value CORT The Nasdaq Stock Mar
• $200 million — approved a program to repurchase up to $200 million of the Company's common stock (the "Sto

Filing Documents

• d45395d8k.htm (8-K) — 26KB
• d45395dex991.htm (EX-99.1) — 11KB
• g45395g0106075508625.jpg (GRAPHIC) — 5KB
• 0001193125-24-003933.txt ( ) — 164KB
• cort-20240108.xsd (EX-101.SCH) — 3KB
• cort-20240108_lab.xml (EX-101.LAB) — 17KB
• cort-20240108_pre.xml (EX-101.PRE) — 11KB
• d45395d8k_htm.xml (XML) — 3KB

02

Item 2.02 Results of Operations and Financial Condition. On January 8, 2024, Corcept Therapeutics Incorporated ("Corcept") issued a press release announcing its preliminary, unaudited, financial results for the quarter and year ended December 31, 2023. The preliminary, unaudited, financial information presented in the press release is based on Corcept's current expectations and may be adjusted as a result of, among other things, completion of customary quarter-end and year-end close review procedures and financial review and completion of the audit of Corcept's 2023 financial statements. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instructions B.2 of Form 8-K, the information in this Item 2.02 of this Current Report on Form 8-K, including the press release attached hereto as Exhibit 99.1, shall be deemed to be "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

01

Item 8.01. Other Events On January 8, 2024, Corcept announced that its Board of Directors approved a program to repurchase up to $200 million of the Company's common stock (the "Stock Repurchase Program"). The Stock Repurchase Program will be in effect commencing on January 10, 2024. The timing and amount of any repurchases pursuant to the Stock Repurchase Program will be determined based on market conditions, the Company's stock price and other factors. The Stock Repurchase Program does not require Corcept to acquire any specific number of shares and it may be modified, suspended or discontinued at any time without notice. Repurchases pursuant to the Stock Repurchase Program may be made through a variety of methods, including open market purchases, privately negotiated transactions, block trades or any combination of such methods.

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits Exhibits No. Description 99.1 Press Release dated January 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CORCEPT THERAPEUTICS INCORPORATED Date: January 8, 2024 By: /s/ Atabak Mokari Name: Atabak Mokari Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR